Please login to the form below

Not currently logged in
Email:
Password:

Merck commits €10m to Israeli biotechs

Merck Serono, a division of Merck, is to support biotech start-ups in Israel with its Israel Bioincubator Fund, a strategic and corporate initiative

Merck Serono, a division of Merck, is to support biotech start-ups in Israel with its Israel Bioincubator Fund, a strategic and corporate initiative. 

The proposal is designed to accelerate the successful development of entrepreneurial start-up companies and will offer both seed financing and the opportunity for biotechs to use a dedicated part of Merck Serono's Israeli research and development centre, Interlab, for their own research.

Israeli biotech companies will be selected based on their potential for developing innovative technologies aligned with the company's strategy, which could enable the discovery and development of new products.

Merck Serono will commit a total of €10m to the bioincubator programme during a seven-year period.

"Because biotech companies and spin-offs from academia in Israel have a high innovation potential, this initiative is very promising for Merck Serono," said Dr Bernhard Kirschbaum, executive vice president of Global Research & Development at Merck Serono. "Our collaboration through the Merck Serono Israel Bioincubator Fund will create exciting opportunities."

Susan Herbert, executive vice president of global portfolio development at Merck Serono, said: "During its long history in Israel, Merck Serono has experienced the willingness of small start-ups to link with larger and more experienced companies that can help them guide product development and company growth. By offering start-ups the funding options and access to more resources that could help move breakthrough concepts into the pre-clinical phase, we can create significant early-stage opportunities and build crucial relations needed for the in-licensing of promising new compounds."

The bioincubator will be launched officially towards the end of 2011. Israeli companies wishing to submit proposals or receive additional information should contact the Merck Serono Israel Bioincubator Fund.

30th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics